Nalaganje...
Proton Pump Inhibitors in IPF: A Call for Clinical Trials
The recent FDA approval of two drugs, pirfenidone and nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF) has fueled interest in the development of additional drugs to treat the disease or its major clinical complications including cough and acute exacerbations. Since 2015, there ar...
Shranjeno v:
| izdano v: | Front Pharmacol |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5966555/ https://ncbi.nlm.nih.gov/pubmed/29867501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00499 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|